Follicular lymphoma treatment market Size Worth USD 3.73 Billion By 2027, According to Latest Study by Emergen Research
According to the current analysis of Emergen research, the global Follicular lymphoma treatment market was valued at USD 2.08 billion in 2019 and is expected to reach USD 3.73 billion by 2027, at a CAGR of 7.6%. Follicular lymphoma is a type of non-Hodgkin’s lymphoma that begins in the B-cells, which are a part of the immune system. These cells are found in the bone marrow and produce antibodies to help fight infection. Follicular lymphoma is the second most common type of non-Hodgkin’s lymphoma.
There are several factors that are driving the growth of the follicular lymphoma treatment market. First, the rising incidence of follicular lymphoma is expected to propel the market growth. According to the American Cancer Society, in 2019, there will be about 7730 new cases of follicular lymphoma in the United States. Second, the availability of advanced treatments is another factor that is expected to fuel the market growth.
For instance, in September 2018, the U.S. Food and Drug Administration (FDA) approved Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. This approval was based on the results of a phase II clinical trial, which showed that axicabtagene ciloleucel resulted in durable responses in patients with relapsed or refractory large B-cell lymphoma. Moreover, the launch of new products is also expected to contribute to the market growth. For instance, in July 2017, Janssen Biotech Inc., a subsidiary of Johnson & Johnson, received FDA approval for Darzalex (daratumumab), an anti-CD38 monoclonal antibody, for the treatment of patients with relapsed or refractory multiple myeloma.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/51
However, the high cost of treatment is expected to restraint the market growth during the forecast period. For instance, according to a report published by the Leukemia & Lymphoma Society in 2018, the cost of CAR T-cell therapy is about USD 373,000.
After the approval of rituximab in 1997, the standard treatment for FL has shifted to first-line therapy with rituximab in combination with chemotherapy. The most commonly used chemotherapy regimens are CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or bendamustine. In the relapsed/refractory setting, the standard of care is rituximab monotherapy or in combination with chemotherapy.
The FL treatment landscape is rapidly evolving with the approval of new agents such as lenalidomide, ibrutinib, and obinutuzumab. Lenalidomide, a thalidomide analog, was approved in 2006 for the treatment of patients with FL who have relapsed after, or are refractory to, a rituximab-containing regimen. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, was approved in 2014 for the treatment of patients with FL who have relapsed after, or are refractory to, a rituximab-containing regimen. Obinutuzumab, a CD20-directed monoclonal antibody, was approved in 2016 for the treatment of patients with FL who have relapsed after, or are refractory to, a rituximab-containing regimen.
Key highlights from the report
- The targeted therapy segment is expected to grow at a CAGR of around 10% during the forecast period due to the rising prevalence of the disease and the increasing demand for targeted therapies. Also, the increasing awareness about the disease and the availability of new treatments are expected to drive the growth of this segment.
- The immunotherapy segment is expected to grow at a CAGR of around 9% during the forecast period due to the rising demand for immunotherapy in the treatment of follicular lymphoma. Also, the availability of immunotherapy drugs is expected to drive the growth of this segment.
- The chemotherapy segment is expected to grow at a CAGR of around 8% during the forecast period due to the increasing use of chemotherapy in the treatment of follicular lymphoma. Also, the rising demand for effective and novel chemotherapy drugs is expected to drive the growth of this segment.
- The radiotherapy segment is expected to grow at a CAGR of around 7% during the forecast period due to the increasing use of radiotherapy in the treatment of follicular lymphoma. Also, the rising demand for effective and novel radiotherapy drugs is expected to drive the growth of this segment.
- The North American follicular lymphoma treatment market is expected to grow at a CAGR of around 10% during the forecast period due to the rising incidence of the disease and the increasing demand for effective and novel treatments.
- The Asia Pacific follicular lymphoma treatment market is growing at a significant rate due to the rising prevalence of blood cancer and the increasing number of cancer patients in the region. According to the World Health Organization (WHO), the incidence of blood cancer is increasing at an alarming rate globally. The number of new cases is estimated to be around 478,000 in 2018, and the number of deaths due to blood cancer is expected to be around 241,000 in 2018.
- Key participants include AbbVie, Inc., Celgene, Bayer AG, Bristol Myers Squibb and Company, Epizyme Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Merck & Co. Inc., and Novartis AG.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/follicular-lymphoma-treatment-market
Emergen research have segmented into the global follicular lymphoma treatment market on the basis of treatment, route of administration, end use, and region:
Treatment Outlook (Revenue, USD million; 2017-2027)
- Monoclonal Antibodies
- Targeted therapy
- Chemotherapy
- Radiation therapy
- Stem cell transplant
- Alkylating Agents
- Nucleoside Analogues
- Anthracycline Derivatives
- Others
Route of Administration Outlook (Revenue, USD million; 2017-2027)
- Oral
- Parenteral
- Others
End Use Outlook (Revenue, USD million; 2017-2027)
- Hospitals
- Oncology Centers
- Ambulatory Care Centers
- Academic Research Institutes
- Others
Regional Outlook (Revenue, USD million; 2017-2027)
- North America
- U.S
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/51
Explore More Reports Emergen Research:
Battery Monitoring System Market
Next-Generation Display Materials Market
Anti-Reflective Coatings Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-follicular-lymphoma-treatment-market